References
- Mirkin B, Weinberger MB. The Demography of Population Ageing [Internet]. Population Division, United Nations Secretariat [cited 2017 Mar 16]. Available from: http://www.un.org/esa/population/publications/bulletin42_43/weinbergermirkin.pdf
- Instituto Nacional de Estadística. Proyecciones de Población 2016–2066 [Internet]. 2016 [cited Oct 25]. Available from: http://www.ine.es/prensa/np994.pdf
- Katz S, Surawicz C, Pardi DS. Management of the elderly patients with inflammatory bowel disease: practical considerations. Inflamm Bowel Dis. 2013;19:2257–2272.
- Katz S, Feldstein R. Inflammatory bowel disease of the elderly: a wake-up call. Gastroenterol Hepatol (NY). 2008;4:337–347.
- Billioud V, Peyrin-Biroulet L. Can elderly people be treated safely with anti-TNF agents? Inflamm Bowel Dis. 2012;18:594–595.
- Cottone M, Kohn A, Daperno M, et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9:30–35.
- Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009;374:1617–1625.
- Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006;55:749–753.
- Stallmach A, Hagel S, Gharbi A, et al. Medical and surgical therapy of inflammatory bowel disease in the elderly—prospects and complications. J Crohn’s Colitis. 2011;5:177–188.
- Sturm A, Maaser C, Mendall M, et al. European Crohn’s and Colitis organisation topical review on IBD in the elderly. J Crohns Colitis 2017;11:263–273.
- Lobatón T, Ferrante M, Rutgeerts P, et al. Efficacy and safety of anti-TNF therapy in elderly patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2015;42:441–451.
- Charpentier C, Salleron J, Savoye G, et al. Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study. Gut 2014;63:423–432.
- Hou JK, Feagins LA, Waljee AK. Characteristics and behavior of elderly-onset inflammatory bowel disease: a multi-center US study. Inflamm Bowel Dis. 2016;22:2200–2205.
- Saad AM, Czul F, Sakuraba A, et al. Age of diagnosis is associated with disease presentation and therapeutic complications in patients with Crohn’s disease. Inflamm Bowel Dis. 2016;22:1027–1031.
- Fumery M, Pariente B, Sarter H, et al. Natural history of crohn's disease in elderly patients diagnosed over the age of 70 years: a population-based STUDY. Inflamm Bowel Dis. 2016;22:1698–1707.
- Juneja M, Baidoo L, Schwartz MB, et al. Geriatric inflammatory bowel disease: phenotypic presentation, treatment patterns, nutritional status, outcomes, and comorbidity. Dig Dis Sci. 2012;57:2408–2415.
- Jeuring SFG, van den Heuvel TRA, Zeegers MP, et al. Epidemiology and long-term outcome of inflammatory bowel disease diagnosed at elderly age-an increasing distinct entity? Inflamm Bowel Dis. 2016;22:1425–1434.
- Rahier JF, Magro F, Abreu C, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohn’s Colitis. 2014;8:443–468.
- Cabriada JL, Vera I, Domènech E, et al. Recommendations of the Spanish working group on crohn’s disease and ulcerative colitis on the use of anti-tumor necrosis factor drugs in inflammatory bowel disease. Gastroenterol Hepatol 2013;36:127–146.
- Cheddani H, Dauchet L, Fumery M, et al. Cancer in elderly onset inflammatory bowel disease: a population-based study. Am J Gastroenterol. 2016;111:1428–1436.
- Galceran J, Ameijide A, Carulla M et al., Redecan working group. Cancer incidence in Spain, 2015. Clin Transl Oncol. 2017;19:799–825.